VERTEX PHARMACEUTICALS INC / MA Acquisitions, Net of Cash Acquired
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Acquisitions, Net of Cash Acquired of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-13.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired · last filed 2025-02-13
- VERTEX PHARMACEUTICALS INC / MA payments to acquire businesses, net of cash acquired for the quarter ending 2023-12-31 was $0.00.
- VERTEX PHARMACEUTICALS INC / MA payments to acquire businesses, net of cash acquired for the quarter ending 2022-12-31 was $0.00.
- VERTEX PHARMACEUTICALS INC / MA payments to acquire businesses, net of cash acquired for the quarter ending 2021-12-31 was $0.00.
- VERTEX PHARMACEUTICALS INC / MA payments to acquire businesses, net of cash acquired for the quarter ending 2020-12-31 was $0.00, a 100.00% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA payments to acquire businesses, net of cash acquired for fiscal 2024 was $0.00.
- VERTEX PHARMACEUTICALS INC / MA payments to acquire businesses, net of cash acquired for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- VERTEX PHARMACEUTICALS INC / MA payments to acquire businesses, net of cash acquired for fiscal 2022 was $295.90M.
- VERTEX PHARMACEUTICALS INC / MA payments to acquire businesses, net of cash acquired for fiscal 2021 was $0.00.
| Period end | Payments to Acquire Businesses, Net of Cash Acquired 3 month | Payments to Acquire Businesses, Net of Cash Acquired 6 month | Payments to Acquire Businesses, Net of Cash Acquired 9 month | Payments to Acquire Businesses, Net of Cash Acquired 12 month | Payments to Acquire Businesses, Net of Cash Acquired 12 month as first filed |
|---|---|---|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-02-13 | ||||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $0.00 10-K · filed 2025-02-13 | |||
| 2023-09-30 | $0.00 10-Q · filed 2023-11-07 | ||||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $295.90M 10-K · filed 2025-02-13 | |||
| 2022-09-30 | $295.90M 10-Q · filed 2023-11-07 | ||||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $0.00 10-K · filed 2024-02-15 | |||
| 2021-09-30 | $0.00 10-Q · filed 2022-10-28 | ||||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-10 | $0.00 10-K · filed 2023-02-10 | |||
| 2020-09-30 | $0.00 10-Q · filed 2020-10-30 | ||||
| 2019-12-31 | $908.38M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | $1.15B 10-K · filed 2022-02-09 | $1.15B 10-K · filed 2020-02-13 | ||
| 2019-09-30 | $245.82M 10-Q · filed 2020-10-30 | ||||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | $0.00 10-K · filed 2021-02-11 | |||
| 2018-09-30 | $0.00 10-Q · filed 2019-10-31 | ||||
| 2017-12-31 | $0.00 10-K · filed 2020-02-13 | ||||
| 2009-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-22 | $0.00 derived: sum of 2 quarters · filed 2012-02-22 | $0.00 derived: sum of 3 quarters · filed 2012-02-22 | $87.42M 10-K · filed 2012-02-22 | |
| 2009-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-28 | $0.00 derived: sum of 2 quarters · filed 2010-10-28 | $87.42M 10-Q · filed 2010-10-28 | ||
| 2009-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2010-08-03 | $87.42M 10-Q · filed 2010-08-03 | |||
| 2009-03-31 | $87.42M 10-Q · filed 2010-05-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |